CN113855663A - Application of oridonin in preparation of anti-prostatic cancer drugs - Google Patents
Application of oridonin in preparation of anti-prostatic cancer drugs Download PDFInfo
- Publication number
- CN113855663A CN113855663A CN202111027762.7A CN202111027762A CN113855663A CN 113855663 A CN113855663 A CN 113855663A CN 202111027762 A CN202111027762 A CN 202111027762A CN 113855663 A CN113855663 A CN 113855663A
- Authority
- CN
- China
- Prior art keywords
- oridonin
- expression
- cells
- mir
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SDHTXBWLVGWJFT-XKCURVIJSA-N oridonin Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12[C@@H](O)CCC(C)(C)[C@H]1[C@H](O)[C@@]3(O)OC2 SDHTXBWLVGWJFT-XKCURVIJSA-N 0.000 title claims abstract description 98
- CAQAFLRZJHXSIS-UHFFFAOYSA-N oridonin Natural products CC1(C)C=CC(O)C23COC(O)(C(O)C12)C45C(O)C(CCC34)C(=C)C5=O CAQAFLRZJHXSIS-UHFFFAOYSA-N 0.000 title claims abstract description 95
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 26
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 230000001826 anti-prostatic effect Effects 0.000 title description 2
- 239000003560 cancer drug Substances 0.000 title description 2
- 230000014509 gene expression Effects 0.000 claims abstract description 57
- 108091031479 miR-204 stem-loop Proteins 0.000 claims abstract description 37
- 102000003945 NF-kappa B Human genes 0.000 claims abstract description 20
- 108010057466 NF-kappa B Proteins 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 18
- 230000019491 signal transduction Effects 0.000 claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 101000674732 Homo sapiens TGF-beta-activated kinase 1 and MAP3K7-binding protein 3 Proteins 0.000 claims description 17
- 102100021229 TGF-beta-activated kinase 1 and MAP3K7-binding protein 3 Human genes 0.000 claims description 17
- 108090000920 TNF receptor-associated factor 1 Proteins 0.000 claims description 17
- 102000004398 TNF receptor-associated factor 1 Human genes 0.000 claims description 16
- 101001072488 Homo sapiens Golgi reassembly-stacking protein 1 Proteins 0.000 claims description 13
- 101001000691 Medicago sativa Pectinesterase Proteins 0.000 claims description 13
- 101000907437 Mycoplasma hyopneumoniae (strain 232) Chaperone protein DnaK Proteins 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 230000001105 regulatory effect Effects 0.000 claims description 13
- 101001018145 Homo sapiens Mitogen-activated protein kinase kinase kinase 3 Proteins 0.000 claims description 12
- 102100033059 Mitogen-activated protein kinase kinase kinase 3 Human genes 0.000 claims description 12
- 206010027476 Metastases Diseases 0.000 claims description 9
- 210000000988 bone and bone Anatomy 0.000 claims description 9
- 230000009401 metastasis Effects 0.000 claims description 9
- 108700005075 Regulator Genes Proteins 0.000 claims description 5
- 230000001276 controlling effect Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 102100036417 Synaptotagmin-1 Human genes 0.000 claims 2
- 108700025695 Suppressor Genes Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 230000009545 invasion Effects 0.000 abstract description 13
- 230000005012 migration Effects 0.000 abstract description 12
- 238000013508 migration Methods 0.000 abstract description 12
- 230000035755 proliferation Effects 0.000 abstract description 11
- 238000000338 in vitro Methods 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 230000000903 blocking effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 14
- 238000000034 method Methods 0.000 description 11
- 102100036698 Golgi reassembly-stacking protein 1 Human genes 0.000 description 7
- 238000011529 RT qPCR Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 5
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101100236409 Homo sapiens MAP3K3 gene Proteins 0.000 description 1
- 101100152311 Homo sapiens TAB3 gene Proteins 0.000 description 1
- 101000800099 Homo sapiens THO complex subunit 1 Proteins 0.000 description 1
- 101100537861 Homo sapiens TRAF1 gene Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001646826 Isodon rubescens Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100029064 Serine/threonine-protein kinase WNK1 Human genes 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 101710124574 Synaptotagmin-1 Proteins 0.000 description 1
- 101150073537 TAB3 gene Proteins 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 101150053233 TRAF1 gene Proteins 0.000 description 1
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 108091048196 miR-5 stem-loop Proteins 0.000 description 1
- 108091082444 miR-5-1 stem-loop Proteins 0.000 description 1
- 108091078363 miR-5-2 stem-loop Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of prostate cancer treatment, in particular to application of oridonin in preparation of a prostate cancer resistant medicament. The invention aims to provide a new choice for treating prostate cancer. The technical scheme of the invention is the application of oridonin in preparing the anti-prostate cancer medicament. The invention verifies that oridonin inhibits the proliferation, migration and invasion of PC-3 cells by up-regulating miR-204-5p expression and blocking NF-kB signal pathway activity. The invention discloses the anti-tumor effect of oridonin on PC-3 cells in vitro, provides possibility for the oridonin as a potential anti-PCa medicament, and provides a new choice for preparing the anti-PCa medicament.
Description
Technical Field
The invention relates to the technical field of prostate cancer treatment, in particular to application of oridonin in preparation of a prostate cancer resistant medicament.
Background
The bone metastasis of Prostate cancer (PCa) is the main cause of death of PCa patients, and the current treatment measures for PCa bone metastasis mainly include surgery, chemotherapy, radiotherapy and the like, wherein chemotherapy is one of the main treatment methods for PCa bone metastasis. However, chemotherapy is easy to cause side effects such as gastrointestinal reaction, neuropathy and the like, so that the exploration of an effective PCa bone metastasis treatment medicament with small toxic and side effects has important clinical significance.
microRNAs are a class of non-coding RNAs widely distributed in eukaryotes that mediate gene degradation or inhibit its translation by binding to the 3' UTR region of the target gene. Researches find that the abnormal expression of the microRNAs is closely related to the occurrence and development of tumors, and can be used as a marker and a therapeutic target for tumor diagnosis.
Oridonin (ORI) is a diterpene active substance isolated from Rabdosia rubescens.
Disclosure of Invention
The invention aims to provide a new choice for treating prostate cancer.
The technical scheme of the invention is the application of oridonin in preparing the anti-prostate cancer medicament.
The invention also provides the application of the oridonin in preparing the medicine for resisting the bone metastasis of the prostate cancer.
The invention also provides a medicament for resisting the prostatic cancer or the prostatic cancer bone metastasis, and the main active component of the medicament is oridonin.
Preferably, the concentration of the oridonin is 5-20 mu M.
More preferably, the concentration of the oridonin is 20 μ M.
The invention further provides application of oridonin in regulation and control of gene miR-204-5p expression and/or NF-kB signal pathway.
Specifically, the expression of the regulatory gene miR-204-5p is the expression of an up-regulated gene miR-204-5 p.
Preferably, the NF- κ B signal pathway is the expression of regulatory genes P65, TRAF1, TAB3 and/or MAP3K 3.
Specifically, the expression of the regulatory gene P65, TRAF1, TAB3 and/or MAP3K3 is the expression of the inhibitory gene P65, TRAF1, TAB3 and/or MAP3K 3.
The invention also provides a composition for regulating and controlling the expression of the gene miR-204-5p and/or the NF-kB signal pathway, and the main active ingredient of the composition is oridonin.
Specifically, in the composition for regulating expression of the gene miR-204-5p, the concentration of oridonin is 5-20 mu M.
Preferably, in the composition for regulating expression of the gene miR-204-5p, the concentration of the oridonin is 10-20 mu M.
Furthermore, in the composition for regulating and controlling the NF-kB signal channel, the concentration of the oridonin is 5-20 mu M.
Preferably, the concentration of the oridonin in the composition for regulating and controlling the NF-kB signal channel is 20 mu M.
The invention has the beneficial effects that: the invention verifies that oridonin inhibits the proliferation, migration and invasion of PC-3 cells by up-regulating miR-204-5p expression and blocking NF-kB signal pathway activity. The invention discloses the anti-tumor effect of oridonin on PC-3 cells in vitro, provides possibility for the oridonin as a potential anti-PCa medicament, and provides a new choice for preparing the anti-PCa medicament.
Drawings
FIG. 1, oridonin inhibits PC-3 cell proliferation; A. the influence of the oridonin solutions with different concentrations on the proliferation capacity of PC-3 cells; B. the effect of oridonin solution on the proliferation ability of PC-3 cells at different times. Wherein, Relative cell promotion (%): relative cell proliferation (%); oridonin (μ M): oridonin (μmol/L); DMSO, DMSO: dimethyl sulfoxide (DMSO).
FIG. 2 shows that oridonin inhibits the migration of PC-3 cells; the A-D, Transwell method is used for evaluating the influence of oridonin solution on PC-3 cell migration; E. migration cell rate. Wherein, Relative migration ratio: (ii) cell mobility; oridonin (μ M): oridonin (μmol/L).
FIG. 3 shows that oridonin inhibits the invasion ability of PC-3 cells; A-D, Transwell method for evaluating the effect of oridonin solution on invasion of PC-3 cells; E. the rate of invading cells. Relative invasion ratio: the rate of cell invasion; oridonin (μ M): oridonin (μmol/L).
FIG. 4 shows that oridonin inhibits NF-kB signal pathway expression by up-regulating miR-204-5 p; A-E, qRT-PCR (polymerase chain reaction) is used for detecting mRNA (messenger ribonucleic acid) expression of miR-204-5p and NF-kB signal channel related genes; F. westernblot detects NF-kB signal channel related protein expression, and p85 is an internal reference. Wherein, Relative miR-204-5P mRNA expression level: relative mRNA expression level of miR-204-5P; relative TRAF1 mRNA expression level: relative mRNA expression levels of TRAF1 gene; relative TAB3 mRNA expression level: the relative mRNA expression level of the TAB3 gene; relative P65 mRNA expression level: relative mRNA expression levels of the P65 gene; relative MAP3K3 mRNA expression level: relative mRNA expression levels of the MAP3K3 gene; oridonin (μ M): oridonin (μmol/L); DMSO, DMSO: dimethyl sulfoxide (DMSO). Vector: empty vector group, miR-204-5P: miR-204-5P overexpression group, DMSO: DMSO group, Oridonin: rubescensin A.
FIG. 5, oridonin inhibits the growth of PC-3 cells in vivo; A. the representative immunohistochemical staining result of the PC-3 cells expressing NF-kB signal channel related genes in vivo by the oridonin solution; B. the weight influence of the oridonin solution on the growth of PC-3 cells in vivo; C. the influence of the oridonin solution on the expression level of miR-204-5p in an animal body; the influence of D-F and oridonin solution on the expression of NF-kB signal channel molecules by PC-3 cells. Tumor weight (mg): tumor body weight (mg); relative miR-204-5P mRNA expression level: relative mRNA expression level of miR-204-5P; relative positive cells field (%): relative percentage (%) of positive cells.
Detailed Description
Reagent, biological material, instrument and apparatus
Human prostate cancer PC-3 cells (purchased from american type culture ATCC collection) were cultured using 1640 medium supplemented with 10% fetal bovine serum, 5% penicillin, and streptomycin (purchased from Gibco, usa); rubescensin A (purchased from Wuhan Huichui Chenopout Bio Inc. of China); RPMI 1640 medium, 0.25% trypsin-EDTA (available from Hyclone, USA); fetal bovine serum, penicillin/streptomycin (available from Gibco, usa); p65, P84, TRAF1, TAB3, and MAP3K3 antibodies (available from Cell Signaling Technology, usa); CCK-8 cell activity detection kit (purchased from Beijing Quanzijin Biotechnology Co., Ltd., China); an RNA extraction kit, a reverse transcription kit and a fluorescent quantitative PCR kit (purchased from Takar, Japan); PCR primers (purchased from Gyka Gene medicine science and technology, China); BCA protein concentration determination kit and hypersensitive ECL chemiluminescence kit (purchased from Biyuntian Biotech, China).
CO2Cell incubator, refrigerated high speed centrifuge, ultra clean biosafety bench (Thermo Fisher, usa), fluorescence microscope (Leica, germany), vertical gel transfer system (Biorad, usa), microplate reader (BioTek, usa).
All experiments below were repeated 3 more times and the data are expressed as mean ± standard deviation. SPSS18.0 was used for analysis, and the differences between groups were compared using the t-test, with P <0.05 representing that the differences were statistically significant.
Example 1: oridonin can inhibit PC-3 cell proliferation
The CCK8 method is used to detect the effect of oridonin solution with different concentrations on cell proliferation capacity. The specific operation method comprises the following steps: cell suspensions were prepared by digesting PC-3 cells with 0.25% pancreatin at 2X 103The cells were plated at a density of 5 per well in 96-well plates. Adding 0, 0.1, 1, 5, 10, 15, 20, 30 and 40 mu mol/L oridonin solution after the cells adhere to the wall, continuously culturing for 24 hours, adding 10 mu L of CCK8 reagent into each hole, incubating for 2 hours,the absorbance at a wavelength of 450nm was then measured using a microplate reader.
The results show that the oridonin inhibits the proliferation of PC-3 cells in a concentration-dependent manner, and the difference has statistical significance compared with a control group (P <0.05), and the IC50 value is about 10 mu M (figure 1A). On the basis, after 0, 1, 2, 3, 4 and 5 days of treatment of the PC-3 cells by using 10 mu M oridonin solution, the proliferation capacity of the cells is detected by using a CCK8 method. The results show that the oridonin inhibits the activity of PC-3 cells in a time-dependent manner, and the difference has statistical significance (P <0.05) compared with the control group (figure 1B).
Example 2: oridonin can inhibit migration and invasion of PC-3 cell
The Transwell experiment is adopted to detect the influence of the oridonin solutions with different concentrations on the migration and invasion capacity of cells. The specific operation method comprises the following steps: treating PC-3 cells with 0, 5, 10, 20 μmol/L oridonin solution for 24 hr, digesting with 0.25% pancreatin, centrifuging, resuspending cell pellet, and adjusting cell density to 1 × 106one/mL. 100 μ L of the cell resuspension was added to the upper Transwell chamber and the culture continued after 800 μ L of cell culture medium was added to the lower chamber. After 24 hours, the Transwell chamber was removed, fixed with 4% paraformaldehyde for 30 minutes, washed, and then the upper cell was carefully removed with a wet cotton swab, stained with 0.1% crystal violet for 20 minutes, dried in the air, and then photographed and counted in an inverted microscope at random in 5 high power fields, and the average value was calculated. In the detection of cell migration capacity, Matrigel is not added in an upper chamber, while in the detection of cell invasion capacity, a Matrigel diluent (1: 5) is required to coat a basement membrane on the upper chamber surface of a Transwell, and other experimental conditions are the same as the operation steps.
The results show that, after PC-3 cells are treated with 0, 5, 10, 20 μ M oridonin solution for 24 hours, oridonin concentration-dependently inhibited cell migration (FIG. 2) and invasion capacity (FIG. 3), and the difference was statistically significant (P <0.05) compared with the control group.
Example 3: oridonin up-regulates miR-204-5p expression and inhibits NF-kB signal channel
qPCR and Western blot experiments are adopted to detect the expression of miR-204-5p and miR-5 p of oridonin solution on cellsThe influence of NF-. kappa.B signaling pathway molecules. The specific operation method comprises the following steps: qPCR experiment: cells were treated with oridonin solutions of various concentrations 0, 5, 10, 15, 20, 30, 40 μmol/L for 24 hours, total RNA was extracted with RNA extraction kit, reverse transcribed into cDNA according to Takara kit, and then amplified using qantifiest SYBR green mix (Qiagen). Relative expression rates of expressed genes of NF-. kappa.B signaling pathway molecules TRAF1, TAB3, P65 and MAP3K3 were examined using U6 or GAPDH as a control, and 2 was used-ΔΔCtCalculated by the method, the primer sequences are shown in the table 1. (II) Western blot experiment: PC-3 cells were seeded to 100cm2Adding 0 and 10 mu mol/L oridonin solution when the cell density is increased to 80 percent in a culture dish, extracting the total cell protein after the drug treatment by utilizing a mixed lysate of RIPA and PMSF after 24 hours, and carrying out protein quantification by using a BCA standard method. 10-12% SDS-PAGE gel was prepared for electrophoresis, PVDF membrane was electroporated for 2 hours, 2% BSA was blocked for 1 hour, primary antibody was added, and incubation was performed in a refrigerator at 4 ℃ in the dark. After washing 3 times with TBST, secondary antibody was added and incubated for 1 hour, ECL luminescence was added and the strips were exposed in an imaging system.
Both the qRT-PCR and Westernblot experimental results show that, after PC-3 cells are treated by oridonin solutions with different concentrations (0, 5, 10, 15 and 20 mu M) for 24 hours, the oridonin solutions up-regulate the expression of miR-204-5P in a concentration-dependent manner, inhibit the expression of NF-kB signal pathway molecules TRAF1, TAB3, P65 and MAP3K3 (figures 4A-E), and have statistical significance (P <0.05) compared with a control group. In addition, both over-expression of miR-204-5P and oridonin can inhibit the expression of TRAF1, TAB3, P65 and MAP3K3 in PC-3 cells, and the regulation and control effects of the two on NF-kB signal pathways are the same (FIG. 4F).
TABLE 1 qRT-PCR primer sequences
Example 4: oridonin has tumor inhibiting effect on nude mouse transplanted tumor and effects of TRAF1, TAB3 and MAP3K3 expression
Male Balb/c nude mice at 6 weeks of age were purchased from the Experimental animals center of Zhongshan university. Mice were randomly assigned toControl group and oridonin treatment group. 0.2mL (1X 10)6Individual) PC-3 cells were inoculated subcutaneously on the back of nude mice. After the tumor of the nude mice is formed, the nude mice with similar tumor volume are selected and randomly grouped, and each group comprises 6 mice. Wherein the control group was not administered any drug; oridonin treatment group, injection according to 4mg/kg standard, 1/1 day, administration of 3 weeks after sacrifice of mice, tumor tissue collection and weighing, TRAF1, TAB3, MAP3K3 and miRNA-204-5p expression level detection, disease immunohistochemical staining. As shown in FIG. 5, the tumor weight of the control group was (289.33 + -48.58) mg, while the volume of the oridonin (500mg/kg) group was (45.35 + -20.13) mg, and the tumor weights of the two groups had statistical significance (FIG. 5B). The qRT-PCR experiment result shows (figure 5C, D) that oridonin (500mg/kg) up-regulates the expression of miRNA-204-5p in nude mouse transplantable tumor, and simultaneously inhibits the expression of NF-kB signal channel downstream genes TRAF1, TAB3 and MAP3K 3. Immunohistochemistry results (fig. 5A) show: compared with the control group, the oridonin groups TRAF1, TAB3 and MAP3K3 protein expression is obviously reduced. Among them, Tumor weight (mg) in FIG. 5: tumor body weight (mg); relative miR-204-5P mRNA expression level: relative mRNA expression level of miR-204-5P; relative positive cells field (%): relative percentage (%) of positive cells.
The applicant explores whether oridonin can inhibit the proliferation, migration and invasion of PC-3 cells in vitro. Firstly, PC-3 cells are treated by oridonin solutions (0, 0.1, 1, 5, 10, 15, 20, 30 and 40 mu M) with different concentrations, and after 24 hours, the influence of the oridonin solutions on the cell proliferation capacity is detected by CCK8, and the result shows that the oridonin solutions inhibit the proliferation of the PC-3 cells in a concentration-dependent manner and have half-inhibition rate IC (integrated circuit) compared with a control group50The value was 10. mu.M. On the basis, after the cells are treated by the 10 mu M oridonin solution for 1 to 5 days, the CCK8 detection result shows that the oridonin solution inhibits the proliferation of PC-3 cells in a time-dependent manner compared with the control group. Secondly, treating the PC-3 cells for 24 hours by using 0, 5, 10 and 20 mu M oridonin solution, and detecting the change of the migration and invasion capacities of the cells by Transwell, wherein the results show that the oridonin solution is in a concentration gradient to inhibit the migration and invasion capacities of the PC-3 cells, and the concentration gradient is 5, 10 and 20 mu MUnder the action of the M oridonin solution, the number of migrated and invaded cells is obviously reduced compared with that of a control group. The results all show that the oridonin can inhibit the proliferation, migration and invasion of PC-3 cells in vitro.
miR-204-5p has an important regulation and control effect in the PCa bone metastasis process, but whether oridonin can influence the transfer capacity of PCa cells by regulating miR-204-5p expression is not clear. Therefore, the invention mainly explores whether oridonin is related to miR-204-5p in inhibiting the proliferation, migration and invasion of PC-3 cells. Firstly, treating PC-3 cells with oridonin solutions with different concentrations (0, 5, 10, 15 and 20 mu M) for 24 hours, and then detecting mRNA expression of miR-204-5p by PCR (polymerase chain reaction), wherein the result shows that the oridonin can up-regulate the expression of miR-204-5p in the PC-3 cells compared with a control group, and the up-regulation effect is most obvious at 10 mu M.
NF- κ B is a key regulator of tumorigenesis, development and metastatic processes. In the invention, PCR results show that oridonin solutions with different concentrations can not only up-regulate miR-204-5P, but also inhibit the expression of genes P65, TRAF1, TAB3 and MAP3K3 downstream of an NF-kB signal channel. In addition, Western blot results show that the oridonin solution treatment group is consistent with the result of over-expression of miR-204-5P, and the expression of molecules P65, TRAF1, TAB3 and MAP3K3 at the downstream of an NF-kB signal channel in a PC-3 cell is obviously reduced compared with a control group. Therefore, the results show that oridonin can up-regulate miR-204-5p to block NF-kB signal pathway molecule expression and participate in regulating the transfer capacity of PC-3 cells.
The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which can be made by those skilled in the art without departing from the spirit and technical spirit of the present invention be covered by the claims of the present invention.
Claims (10)
1. Application of oridonin in preparing medicine for treating prostatic cancer is provided.
2. Application of oridonin in preparing medicine for resisting bone metastasis of prostatic cancer is provided.
3. A medicine for resisting prostatic cancer or bone metastasis of prostatic cancer comprises oridonin as main active ingredient;
the concentration of the oridonin is 5-20 mu M.
4. The application of oridonin in regulating gene miR-204-5p expression and/or NF-kB signal pathway.
5. The use of claim 4, wherein the regulatory gene miR-204-5p expression is an up-regulated gene miR-204-5p expression.
6. The use of claim 4, wherein the modulating NF- κ B signaling pathway is modulating expression of genes P65, TRAF1, TAB3 and/or MAP3K 3.
7. Use according to claim 6, wherein the expression of the regulatory gene P65, TRAF1, TAB3 and/or MAP3K3 is the expression of the suppressor gene P65, TRAF1, TAB3 and/or MAP3K 3.
8. The composition for regulating and controlling gene miR-204-5p expression and/or NF-kB signal pathway is characterized in that the main active component is oridonin;
in the composition for regulating the expression of the gene miR-204-5p, the concentration of the oridonin is 5-20 mu M.
9. The composition of claim 8, wherein the concentration of oridonin in the composition for regulating expression of gene miR-204-5p is 10-20 μ M.
10. The composition of claim 9, wherein the concentration of oridonin in the composition for modulating the NF- κ B signaling pathway is 5-20 μ Μ.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111027762.7A CN113855663A (en) | 2021-09-02 | 2021-09-02 | Application of oridonin in preparation of anti-prostatic cancer drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111027762.7A CN113855663A (en) | 2021-09-02 | 2021-09-02 | Application of oridonin in preparation of anti-prostatic cancer drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113855663A true CN113855663A (en) | 2021-12-31 |
Family
ID=78989388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111027762.7A Pending CN113855663A (en) | 2021-09-02 | 2021-09-02 | Application of oridonin in preparation of anti-prostatic cancer drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113855663A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115887428A (en) * | 2022-12-16 | 2023-04-04 | 遵义医科大学第二附属医院 | Application of cinnamaldehyde in preparing medicine for resisting bone metastasis of prostate cancer |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105713006A (en) * | 2014-12-05 | 2016-06-29 | 鲁艳清 | Preparation method of oridonin |
| CN108938660A (en) * | 2018-07-09 | 2018-12-07 | 广州医科大学附属第二医院 | MiR-204-5p is preparing the application in NF- kB inhibitor and prostate cancer transfer prevention and treatment |
-
2021
- 2021-09-02 CN CN202111027762.7A patent/CN113855663A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105713006A (en) * | 2014-12-05 | 2016-06-29 | 鲁艳清 | Preparation method of oridonin |
| CN108938660A (en) * | 2018-07-09 | 2018-12-07 | 广州医科大学附属第二医院 | MiR-204-5p is preparing the application in NF- kB inhibitor and prostate cancer transfer prevention and treatment |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115887428A (en) * | 2022-12-16 | 2023-04-04 | 遵义医科大学第二附属医院 | Application of cinnamaldehyde in preparing medicine for resisting bone metastasis of prostate cancer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ge et al. | AntagomiR-27a targets FOXO3a in glioblastoma and suppresses U87 cell growth in vitro and in vivo | |
| CN107586781B (en) | Liver cancer marker lncRNA ENST00000620463.1 and application thereof | |
| CN113855663A (en) | Application of oridonin in preparation of anti-prostatic cancer drugs | |
| CN112867495A (en) | Gastric cancer therapeutic composition comprising SYT11 inhibitor as active ingredient | |
| CN109055561A (en) | LncRNA-AP003774.1 is diagnosing and/or treating the application in breast cancers | |
| CN116479130A (en) | Coiled-coil forming protein kinase ROCK1 as pancreatic cancer tumor marker and application thereof | |
| Huang et al. | Effects of hTERT antisense oligodeoxynucleotide on cell apoptosis and expression of hTERT and bcl-2 mRNA in keloid fibroblasts. | |
| CN110628791B (en) | Application of tRNA (transfer RNA) modified enzyme gene in non-small cell lung cancer | |
| CN109295220B (en) | Application of miR-495-5p in preparation of products for diagnosing, prognosing, preventing or treating pancreatic cancer | |
| CN113637763A (en) | Application of miRNA biomarker in early diagnosis and treatment of melanoma | |
| CN113318104A (en) | Application of sulconazole and/or sulconazole salt in preparing medicine for treating esophageal squamous cell carcinoma | |
| KR102591642B1 (en) | Targets and their applications for drug treatment of tumor metastases | |
| CN109172593B (en) | Application of miR-516a as target for treating bladder cancer | |
| CN107190009B (en) | siRNA for inhibiting migration of human colorectal cancer cells by silencing ARPC4 gene and application thereof | |
| CN105671195B (en) | Purposes, pharmaceutical composition and the kit of miR-520c nucleotide | |
| CN109999023A (en) | II type polyketide of halogenation is inhibiting the application in Cells Proliferation of Human Breast Cancer | |
| CN113440511B (en) | HOTAIR-PRC2 blocker and application of compound preparation thereof in preparation of endometrial cancer treatment drug | |
| CN116004811B (en) | Application of ZDHC 9 interference fragment in preparation of PD-L1 monoclonal antibody tumor immunotherapy medicament | |
| CN109554364B (en) | TSNAX gene inhibitor and application thereof in tumors | |
| CN110079528B (en) | Application of small interfering RNA (ribonucleic acid) targeting OTUD7B gene in glioma targeted therapy | |
| CN104436216B (en) | The Expression modulation agent of transcription factor Yin Yang 1 is used as glycometabolism adjusting control agent | |
| CN118001378B (en) | Use of substances overexpressing MOCS a in the preparation of a product for the treatment of diseases induced by helicobacter pylori infection | |
| CN114085832B (en) | SiRNA molecules for inhibiting PRR14 gene | |
| KR101862247B1 (en) | Pharmaceutical Composition for Treating Cancer Comprising miRNA having Drug Response to serpinb5 and Application Thereof | |
| CN110420328B (en) | Application of SYT14 inhibitor in preparation of medicine for treating lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211231 |